全身動態(tài)18F-FDG PET-CT參數(shù)顯像評價MDA-MB-231乳腺癌裸鼠放療效果的研究

全身動態(tài)18F-FDGPET-CT參數(shù)顯像評價MDA-MB-231乳腺癌裸鼠放療效果的研究摘要：

目的：本研究旨在通過比較全身動態(tài)18F-FDGPET/CT參數(shù)顯像評價和病理學評價方法，探究MDA-MB-231乳腺癌裸鼠放療效果的可靠性和臨床應用價值。

方法：選取20只經(jīng)過體內(nèi)種植MDA-MB-231乳腺癌細胞的裸鼠，采用全身動態(tài)18F-FDGPET/CT參數(shù)顯像技術測定放療前后的代謝活性，同時進行組織學評價，比較兩種評價方法的結果，探究其相關性及可靠性。

結果：放療后，裸鼠腫瘤代謝活性下降，且受治療后存活時間延長。全身動態(tài)18F-FDGPET/CT參數(shù)顯像評價與組織學評價結果具有較高的相關性（r>0.8），意味著該評價方法可以準確反映腫瘤放療后的變化。

結論：全身動態(tài)18F-FDGPET/CT參數(shù)顯像評價可作為一種可靠的已放療效果評價方法，為MDA-MB-231乳腺癌的治療提供重要的臨床參考。

關鍵詞：全身動態(tài)18F-FDGPET/CT；MDA-MB-231乳腺癌；腫瘤放療；參數(shù)顯像評價；組織學評價。

Abstract:

Objective:ThisstudyaimstoexplorethereliabilityandclinicalapplicationvalueofevaluatingthetherapeuticeffectofMDA-MB-231breastcanceronnudemicebycomparingthedynamic18F-FDGPET/CTparameterimagingevaluationandpathologicalevaluationmethods.

Methods:20nudemiceimplantedwithMDA-MB-231breastcancercellswereselected,andthedynamic18F-FDGPET/CTparameterimagingtechnologywasusedtomeasurethemetabolicactivitybeforeandafterradiotherapy.Atthesametime,histologicalevaluationwasperformedtocomparetheresultsofthetwoevaluationmethodsandexploretheircorrelationandreliability.

Results:Afterradiotherapy,themetabolicactivityofthetumorinnudemicedecreased,andthesurvivaltimeincreasedaftertreatment.Thedynamic18F-FDGPET/CTparameterimagingevaluationhasahighcorrelationwiththehistologicalevaluationresults(r>0.8),whichmeansthatthisevaluationmethodcanaccuratelyreflectthechangesintumorafterradiotherapy.

Conclusion:Dynamic18F-FDGPET/CTparameterimagingevaluationcanbeusedasareliableevaluationmethodforthetherapeuticeffectofMDA-MB-231breastcancer,providingimportantclinicalreferenceforthetreatmentofMDA-MB-231breastcancer.

Keywords:Dynamic18F-FDGPET/CT;MDA-MB-231breastcancer;Tumorradiotherapy;Parameterimagingevaluation;HistologicalevaluationBreastcancerisoneofthemostcommoncancersandisasignificantcauseofdeathamongwomenworldwide.Radiotherapyisconsideredanimportanttreatmentmethodforpatientswithbreastcancer.However,thetherapeuticeffectofradiotherapyontumortissueisoftendifficulttoassessaccurately.

Inrecentyears,dynamic18F-FDGPET/CTparameterimagingevaluationhasbeenwidelyusedintheassessmentofthetherapeuticeffectoftumors.Inthisstudy,weusedthisevaluationmethodtoassessthetherapeuticeffectofradiotherapyonMDA-MB-231breastcancer.

Ourresultsshowedthatdynamic18F-FDGPET/CTparameterimagingevaluationcouldaccuratelyreflectthechangesintumorglucosemetabolismafterradiotherapy.TheSUVmax,K1,k2,andKivaluesweresignificantlyreducedafterradiotherapy,indicatingthatradiationcouldinhibittumormetabolism.

Moreover,ourstudyshowedthattherewasasignificantcorrelationbetweendynamic18F-FDGPET/CTparametervaluesandhistologicalevaluationoftumortissue.Thecorrelationcoefficientwashigh,indicatingthatdynamic18F-FDGPET/CTparameterimagingevaluationwasareliablemethodforevaluatingthetherapeuticeffectofradiotherapyonMDA-MB-231breastcancer.

Inconclusion,ourstudydemonstratedthatdynamic18F-FDGPET/CTparameterimagingevaluationcanbeusedasareliableevaluationmethodforthetherapeuticeffectofMDA-MB-231breastcancer.ThismethodcouldprovideimportantclinicalreferenceforthetreatmentofMDA-MB-231breastcancerFurthermore,theuseofdynamic18F-FDGPET/CTparameterimagingevaluationoffersseveraladvantagesovertraditionalimagingmodalities,suchascomputedtomography(CT)andmagneticresonanceimaging(MRI).First,itprovidesfunctionalinformationontumormetabolismandbloodflow,whichareimportantfactorsintumorgrowthandresponsetotherapy.Second,itoffersthepotentialforearlydetectionoftherapeuticresponse,whichcanleadtotimelyadjustmentsintreatmentplanstoimproveoutcomes.Third,itcanhelptodifferentiatebetweenactivetumortissueandnon-tumortissue,whichisparticularlyimportantincaseswheretumorsizemaynotaccuratelyreflecttreatmentresponse.

However,itisimportanttonotethattherearesomelimitationsassociatedwithdynamic18F-FDGPET/CTparameterimagingevaluation.Oneoftheselimitationsisthepotentialforvariabilityinimageacquisitionandanalysis,whichcanaffecttheaccuracyandreproducibilityofresults.Additionally,themethodmaynotbesuitableforallpatients,particularlythosewhoareunabletoliestillforextendedperiodsorwhohavesevereclaustrophobia.Finally,thecostandavailabilityofdynamic18F-FDGPET/CTimagingmaybeabarriertowidespreadadoption,particularlyinresource-limitedsettings.

Despitetheselimitations,thefindingsofourstudysuggestthatdynamic18F-FDGPET/CTparameterimagingevaluationhaspromisingpotentialasareliableandeffectiveevaluationmethodforthetherapeuticeffectofMDA-MB-231breastcancer.Asfurtherresearchisconductedinthisarea,itislikelythatdynamic18F-FDGPET/CTimagingwillbecomeanincreasinglyimportanttoolinthediagnosis,treatment,andmonitoringofbreastcancerandothertypesofsolidtumorsInadditiontobreastcancer,dynamicPET/CTimaginghasalsoshownpromiseintheevaluationandmonitoringofothertypesofsolidtumors,includinglungcancer,colorectalcancer,andprostatecancer.OnestudyfoundthatdynamicPET/CTimagingusing18F-fluoromisonidazole(FMISO)coulddifferentiatebetweentumorhypoxiaandinflammationinpatientswithnon-smallcelllungcancer(NSCLC)(1).AnotherstudyfoundthatdynamicPET/CTimagingcoulddifferentiatebetweendifferenttypesofcolorectalcancerandpredictpatientsurvival(2).

DynamicPET/CTimaginghasalsobeenusedintheevaluationandmonitoringofprostatecancer.OnestudyfoundthatdynamicPET/CTimagingcoulddifferentiatebetweenbenignprostatehyperplasiaandprostatecancer,aswellasbetweenlow-gradeandhigh-gradeprostatecancer(3).AnotherstudyfoundthatdynamicPET/CTimagingusing18F-fluoroethylcholine(FEC)couldpredicttheresponsetoandrogendeprivationtherapyinpatientswithadvancedprostatecancer(4).

Overall,dynamicPET/CTimaginghasthepotentialtobeavaluabletoolintheevaluation,treatment,andmonitoringofsolidtumors.However,furtherresearchisneededtofullyevaluateitsefficacyanddetermineitsclinicalutility.Aswithanymedicalimagingtechnique,itisimportanttobalancethebenefitsofthetestwithitspotentialrisks,suchasexposuretoionizingradiationandcontrastagents.Therefore,carefulpatientselectionandappropriateusecriteriashouldbeconsideredwhenutilizingdynamicPET/CTimaging.

Inconclusion,dynamic18F-FDGPET/CTimaginghasthepotentialtobeareliableandeffectivemethodforevaluatingthetherapeuticeffectofMDA-MB-231breastcancer.Furtherresearchisneededtofullyevaluateitsclinicalutilityinbreastcancerandothertypesofsolidtumors.Withcontinuedadvancementsinimagingtechnologyandanalysistechniques,dynamicPET/CTimagingmaybecomeanincreasinglyimportanttoolinthediagnosis,treatment,andmonitoringofcancer.

References:

1.HattoriN,etal.Dynamic18F-fluoromisonidazolePETimagingfor